Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Fixed drug eruption

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Generalised bullous fixed eruption

Widespread dusky plaques, blistering, epidermal loss or mucosal involvement can resemble SJS or TEN and cause clinically important skin failure.

Action: Stop suspected medicines, obtain urgent dermatology and acute-medical assessment, monitor physiology and manage extensive erosions in an appropriate hospital setting.

Synopsis

Recognise site-specific recurrence after medicine exposure, distinguish local fixed eruption from generalised bullous disease, and document the culprit and residual pigmentation accurately.

  • A fixed drug eruption recurs at the same sharply demarcated skin or mucosal site after re-exposure and usually leaves residual hyperpigmentation.
  • Active lesions may be red, violaceous, dusky brown or blistered; ask the patient whether a dark mark was present before the current flare.
  • Search intermittent medicines, analgesics, antibiotics, supplements and combination cold remedies used in the hours or days before every episode.
  • One episode may involve one plaque, but additional sites often appear with later exposures and generalised bullous disease can be life-threatening.
  • Do not perform casual oral re-challenge when the original reaction was bullous, generalised or involved mucosa.
  • Record the specific suspected drug, recurrence pattern, sites, severity and uncertainty, with photographs obtained after consent.
  • Fixed drug eruption must be assessed by lesion duration, onset, distribution, symptoms, mucosal findings, systemic physiology and the full medicine timeline rather than by colour alone.
  • For Fixed drug eruption, document the working diagnosis, excluded emergencies, uncertain culprit or trigger, treatment response and the exact safety-net given.

Key red flags

Numerous lesions, generalised blistering, mucosal erosions, skin pain, fever, dehydration or diagnostic uncertainty with SJS or TEN requires same-day hospital assessment.

Generalised bullous warning

Multiple tender dusky plaques with extensive blisters, detachment or mucosal injury require urgent SJS or TEN-level assessment.

Investigation priorities

01
Episode-specific medicine tableFirst step

Demonstrate repeated exposure before recurrence at a fixed site.

Management branches

Localised stable episodeStop the likely trigger and calm inflammation

One or few fixed plaques occur without fever, mucosal loss, widespread blistering or systemic illness.

  1. Construct a precise recurrent-exposure history, stop the likely non-essential culprit and identify all combination products containing it.
  2. Use cool care, emollient and a site-appropriate topical corticosteroid for short-term symptoms while monitoring for new lesions.
  3. Photograph with consent, explain residual pigment and arrange review if the eruption spreads, blisters or affects mucosa.

Key medicines

Betamethasone valerate 0.1% creamApply thinly to a localised intact plaque once or twice daily for the shortest effective course, not exceeding four weeks under the licensed product directions.Avoid application to eroded mucosa, infected skin, face or large areas unless directed; review atrophy and systemic absorption, especially under occlusion.
Cetirizine 10 mg tabletsAdults and adolescents aged 12 years and over take 10 mg orally once daily, with renal adjustment as specified by the product information.Review drowsiness, alcohol, driving, renal function, pregnancy and breastfeeding; do not interpret symptom relief as evidence that bullous progression is safe.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG183 drug allergy diagnosis and managementAssessment, documentation, referral and future avoidance.
  • NHS Borders recurrent anogenital ulcer guidanceFixed-drug recurrence history and important ulcer differentials.
  • Betamethasone valerate 0.1 percent cream SmPCTopical potency, duration and application safeguards.
  • Cetirizine 10 mg tablets SmPCLicensed dosing, renal adjustment and adverse effects.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom